1. Home
  2. Analysis
  3. Adriamycin-pfs
  4. Revlimid

Adriamycin pfs and Revlimid drug interactions for women aged 40-49 (a phase IV clinical study of FDA data)

Summary:

Drug interactions are found for women aged 40-49 who take Adriamycin pfs (doxorubicin hydrochloride) and Revlimid (lenalidomide) together. We list drug interactions by the duration when the drugs are taken. This phase IV study is created by eHealthMe based on reports of 7 people from the FDA, and is updated regularly.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

7 women aged 40-49 who take Adriamycin pfs, Revlimid and have drug interactions are studied.

What is Adriamycin pfs?

Adriamycin pfs has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 6,495 Adriamycin pfs users. Check the latest studies of Adriamycin pfs.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

Number of reports submitted per year:

Adriamycin pfs and Revlimid drug interactions in women aged 40-49.

Most common drug interactions over time *:

< 1 month:

  1. Pyrexia (fever)
  2. Stomatitis (inflammation of mucous membrane of mouth)

1 - 6 months:

  1. Blood human chorionic gonadotropin increased
  2. Fatigue (feeling of tiredness)

6 - 12 months:

  1. Cardiac disorder

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

  1. Blood human chorionic gonadotropin increased
  2. Cardiomyopathy (weakening of the heart muscle)
  3. Fatigue (feeling of tiredness)
  4. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  5. Plasmacytoma (neoplasm of plasma cells (usually in bone marrow))

* Approximation only. Some reports may have incomplete information.

Do you take Adriamycin pfs and Revlimid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies:

How the study uses the data?

The study is based on (applicable) gender, age, doxorubicin hydrochloride and lenalidomide (the active ingredients of Adriamycin pfs and Revlimid, respectively), and Adriamycin pfs and Revlimid (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.